The trials for this new TB vaccine have been taking place in sub-Saharan Africa for several years and the long-term Phase 2b results have finally been published.

Tuberculosis (TB) is the world's deadliest infectious disease, killing 1.25 million people in 2023. MTBVAC is a promising vaccine candidate being evaluated in the IMAGINE trial, a large-scale ...